GeoVax Labs (GOVX) to Release Quarterly Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) is projected to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($7.00) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

GeoVax Labs Trading Down 15.5%

GOVX stock opened at $1.42 on Thursday. GeoVax Labs has a twelve month low of $1.26 and a twelve month high of $37.75. The company has a market capitalization of $2.58 million, a P/E ratio of -0.04 and a beta of 3.81. The firm has a 50 day simple moving average of $2.35 and a 200-day simple moving average of $8.69.

Institutional Trading of GeoVax Labs

Institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs in the 4th quarter worth approximately $104,000. Jane Street Group LLC bought a new position in GeoVax Labs during the 4th quarter worth $99,000. Armistice Capital LLC acquired a new stake in GeoVax Labs in the third quarter worth $253,000. Finally, HRT Financial LP acquired a new stake in GeoVax Labs in the fourth quarter worth $31,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on GOVX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Finally, D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, February 19th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GeoVax Labs presently has an average rating of “Hold” and a consensus price target of $187.50.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.